FDA ApprovedUnited States
New Muscle-Targeted IV Treatment for SMA Ages 2 and Up
Isembyld (apitegromab-mstn) — a once-every-4-weeks IV medicine that targets muscle for people with SMA already on an SMN2 treatment
FDA approval on 11 September 2026 for Isembyld (apitegromab-mstn) injection — a muscle-targeted intravenous medicine — for spinal muscular…
This is for children and adults living with SMA who are already on an SMN2-targeted treatment (such as…